Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Jarrod Mousa · UNIVERSITY OF GEORGIA · 2023 · $134,666 — The goal of this research project is to further the development of a pan-Pneumovirus vaccine and to test our hypothesis that a chimeric Pneumovirus fusion (F) protein vaccine displaying immunodominant epitopes of respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) will induce broad pr…
GEORGE ENG · MASSACHUSETTS GENERAL HOSPITAL · 2023 · $196,204 — Project Summary/Abstract This proposal details a five-year training plan for the development of a research program focused on elucidating the therapeutic potential of superimposed additional Wnt signaling on colonic neoplasia. The molecular driver shared across the vast majority of colonic neoplasms…
SANJAY RAM · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2023 · $265,676 — PROJECT SUMMARY/ABSTRACT About 87 million new cases of gonorrhea occur worldwide annually. In 2020, 677,769 cases were reported to the CDC, a 111% increase in annual incidence since the historic low in 2009. Neisseria gonorrhoeae (Ng) has become resistant to almost every antibiotic in clinical use. …
Beth Ann Tamburini · UNIVERSITY OF COLORADO DENVER · 2023 · $72,505 — Project summary: We and others have demonstrated that antigens derived from infectious viral infections persist in the host for extended periods of time, well beyond the time in which the infection is cleared from the host. Our lab has specifically identified that antigens derived from both vaccinat…
Kenneth C Bagley · ORLANCE, INC. · 2023 · $996,500 — PROJECT SUMMARY Orlance has developed a lead universal influenza (UFlu) DNA vaccine to address the need for a vaccine that can protect from annual influenza and the emergence of new variants that could cause future pandemics. Our UFlu vaccine is a multi-dose vaccine designed to induce systemic and m…
Jonathan D. Kurtis · BROWN UNIVERSITY · 2023 · $500,144 — ABSTRACT The goal of this R01 application is to discover the targets of naturally acquired protection against severe Plasmodium falciparum malaria and to develop them as novel blood-stage vaccine candidates. Of the ~100 malaria vaccine candidates currently under investigation, more than 60% are bas…
Peter B. Gilbert · FRED HUTCHINSON CANCER CENTER · 2023 · $12,647,369 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the COVID-19 vaccine efficacy trial entitled “Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with …
Siyuan Ding · WASHINGTON UNIVERSITY · 2023 · $77,750 — Project Summary From the parent grant: Rotaviruses (RVs) are a medically important human pathogen and the predominant cause of severe gastroenteritis, vomiting, and diarrhea in infants and young children worldwide. RVs are also a great model to interrogate the antiviral responses at the host mucosa…
Kenneth C Bagley · ORLANCE, INC. · 2023 · $200,000 — PROJECT SUMMARY Orlance has developed a next-generation Gene Gun (MACH-1 GG) that efficiently delivers DNA and RNA into epidermal cells, leading to robust immune responses. Sequencing of tumors from individual patients has led to the identification of personalized neoantigens that could be targeted …
Colleen M. Lau · CORNELL UNIVERSITY · 2023 · $108,000 — PROJECT SUMMARY The candidate, Dr. Colleen Lau seeks to achieve an academic career as an independent research investigator at an institution where she can foster academic growth and immunology research that advances treatment or prevention of human disease. She aims to do so through a union of labo…
Gabriel D Victora · ROCKEFELLER UNIVERSITY · 2023 · $797,082 — PROJECT SUMMARY Generation of high affinity antibodies in germinal centers (GCs) is a critical step in a wide variety of clinically relevant processes, from protection against pathogens by prior infection or vaccination to the development of allergies and autoimmune diseases. Antibody affinity matur…
Jesus Valenzuela · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $1,281,901 — The accomplishment of the section are: 1. We developed a novel biomarker for sand fly exposure in humans using two recombinant salivary proteins from the sand fly Phlebotomus argentipes. To develop this tool, we identified PagSP02 and PagSP06 from saliva of Phlebotomus argentipes, the vector of Lei…
Masaru Kanekiyo · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $4,261,000 — Improvements in vaccines against influenza that increase potency, breadth and durability of protection would improve worldwide ability to combat seasonal influenza as well as emergence of new pandemic influenza viruses. Influenza vaccines have the potential to reduce the risk of symptomatic infectio…
RICHARD CHILDS · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2023 · $4,208,801 — Approximately 20 years ago, we initiated the first ever clinical trail investigating allogeneic stem cell transplantation in patients with treatment refractory metastatic renal cell carcinoma (RCC). Definitive evidence for an allogeneic graft-versus-RCC effect has been demonstrated with complete reg…
Chi Li · UNIVERSITY OF LOUISVILLE · 2023 · $219,491 — PROJECT SUMMARY/ABSTRACT Lung cancer is a prevalent disease and consume many lives every year. Disease relapse, invasion and metastases are the main causes of death. Recent discoveries provide compelling evidence that at least some types of cancer are initiated and maintained by a small population …
Ranjit Ray · SAINT LOUIS UNIVERSITY · 2023 · $340,875 — Abstract Chronic hepatitis C virus (HCV) infection often causes end stage liver disease. Although current anti-HCV drugs are successful in eliminating viral RNA load, they do not prevent reinfection. In addition, eliminating HCV RNA load does not reduce the risk for progression to end stage liver di…
Margaret Juliana McElrath · FRED HUTCHINSON CANCER CENTER · 2023 · $3,200,000 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the COVID-19 vaccine efficacy trial, CoVPN 3008 (the Ubuntu study) entitled “Multi-Center, Randomized, Efficacy Study of COVID-1…
Jacob Brenner · NANOMUSE, LLC · 2023 · $300,454 — ABSTRACT / PROJECT SUMMARY Acute ischemic stroke is poised for a revolution. With the advent of mechanical thrombectomy in the last decade, the worst clots can be removed. While thrombectomy has improved outcomes, most treated patients still have severe deficits, in large part due to secondary inju…
Annaliese Franz · UNIVERSITY OF CALIFORNIA AT DAVIS · 2023 · $76,496 — PROJECT ABSTRACT Liposomes, including nucleic acid complexed lipid nanoparticles (LNPs) have shown success in drug delivery and formulation of sensitive RNA-based therapeutics, including the recent example of the mRNA Sar-COV-2 vaccine. The goal of this proposal is to synthesize and evaluate novel s…
Sean Alex Gray · PAI LIFE SCIENCES, INC. · 2023 · $300,000 — ABSTRACT Schistosomiasis is a major parasitic disease which could impact one billion people with 252 million currently infected and 779 million at risk to acquire the infection in 74 countries. Current control strategies have relied on repeated treatments with the drug praziquantel alone – however, …